» Articles » PMID: 39843468

Integrated Cancer Cell-specific Single-cell RNA-seq Datasets of Immune Checkpoint Blockade-treated Patients

Overview
Journal Sci Data
Date 2025 Jan 22
PMID 39843468
Authors
Affiliations
Soon will be listed here.
Abstract

Immune checkpoint blockade (ICB) therapies have emerged as a promising avenue for the treatment of various cancers. Despite their success, the efficacy of these treatments is variable across patients and cancer types. Numerous single-cell RNA-sequencing (scRNA-seq) studies have been conducted to unravel cell-specific responses to ICB treatment. However, these studies are limited in their sample sizes and require advanced coding skills for exploration. Here, we have compiled eight scRNA-seq datasets from nine cancer types, encompassing 223 patients, 90,270 cancer cells, and 265,671 other cell types. This compilation forms a unique resource tailored to investigate how cancer cells respond to ICB treatment across cancer types. We meticulously curated, quality-checked, pre-processed, and analyzed the data, ensuring easy access for researchers. Moreover, we designed a user-friendly interface for seamless exploration. By sharing the code and data for creating these interfaces, we aim to assist fellow researchers. These resources offer valuable support to those interested in leveraging and exploring single-cell datasets across diverse cancer types, facilitating a comprehensive understanding of ICB responses.

Citing Articles

Integrated cancer cell-specific single-cell RNA-seq datasets of immune checkpoint blockade-treated patients.

Gondal M, Cieslik M, Chinnaiyan A Sci Data. 2025; 12(1):139.

PMID: 39843468 PMC: 11754430. DOI: 10.1038/s41597-025-04381-6.


A Systematic Overview of Single-Cell Transcriptomics Databases, their Use cases, and Limitations.

Gondal M, Shah S, Chinnaiyan A, Cieslik M ArXiv. 2024; .

PMID: 38699169 PMC: 11065044.

References
1.
Van Allen E, Miao D, Schilling B, Shukla S, Blank C, Zimmer L . Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211. PMC: 5054517. DOI: 10.1126/science.aad0095. View

2.
Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

3.
Alvarez-Breckenridge C, Markson S, Stocking J, Nayyar N, Lastrapes M, Strickland M . Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition. Cancer Immunol Res. 2022; 10(8):996-1012. PMC: 10201927. DOI: 10.1158/2326-6066.CIR-21-0870. View

4.
Fyfe G, Fisher R, Rosenberg S, Sznol M, Parkinson D, Louie A . Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995; 13(3):688-96. DOI: 10.1200/JCO.1995.13.3.688. View

5.
Gondal M, Chaudhary S . Navigating Multi-Scale Cancer Systems Biology Towards Model-Driven Clinical Oncology and Its Applications in Personalized Therapeutics. Front Oncol. 2021; 11:712505. PMC: 8652070. DOI: 10.3389/fonc.2021.712505. View